Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01432457 · ClinicalTrials.gov registry record · Phase 4
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 924
- Enrollment target
NCT01432457 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 924 participants.
The verdict
NCT01432457, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 924 participants
- Enrollment target
Study Summary
A multicenter, 8-week study to evaluate the efficacy of 2 doses (50 and 100 mg/day) of desvenlafaxine succinate sustained-release (DVS SR) versus placebo in adult outpatients with major depressive disorder.
Interventions
- DRUG placebo
- DRUG desvenlafaxine succinate sustained-release 50 mg/day
- DRUG desvenlafaxine succinate sustained-release 100 mg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 924 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01432457
The ClinicalTrials.gov registry entry for NCT01432457 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 924 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01432457 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01432457 about?
NCT01432457 is a clinical study titled "Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)". A multicenter, 8-week study to evaluate the efficacy of 2 doses (50 and 100 mg/day) of desvenlafaxine succinate sustained-release (DVS SR) versus placebo in adult outpatients with major depressive disorder.
What is the current status of trial NCT01432457?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 924 participants. The study started on 2011-10. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01432457?
The interventions under investigation include: placebo (DRUG), desvenlafaxine succinate sustained-release 50 mg/day (DRUG), desvenlafaxine succinate sustained-release 100 mg/day (DRUG).
Who is sponsoring clinical trial NCT01432457?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.